Lead Sponsor

Ra Pharmaceuticals

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of gMG \[Myasthenia Gravis Foundation of America (MGFA) Class II-IVa\] at Screening
•Positive serology for acetylcholine receptor (AChR) autoantibodies
•QMG score ≥ 12 at Screening and Randomization
•No change in corticosteroid dose for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period
•No change in immunosuppressive therapy, including dose, for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period

•Thymectomy within 6 months prior to Randomization or scheduled to occur during the 12 week Treatment Period
•History of meningococcal disease
•Current or recent systemic infection within 2 weeks prior to Randomization or infection requiring intravenous (IV) antibiotics within 4 weeks prior to Randomization

Related studies

NCT06312644 · Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, and more

NCT07247279 · Rare Diseases, Generalized Myasthenia Gravis (gMG)

NCT06149559 · Generalized Myasthenia Gravis

NCT06055959 · Generalized Myasthenia Gravis

NCT04833894 · Generalized Myasthenia Gravis

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis